Search
Pregabalin
go.drugbank.com/drugs/DB00230ApprovedInvestigational[A187190] Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent … [L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161]
Mixtures: PRIKUL DUOLifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigational] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Tenocyclidine
go.drugbank.com/drugs/DB01520IllicitInvestigationalIt is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Categories: Compounds used in a research, industrial, or household settingORM-13070 C-11
go.drugbank.com/drugs/DB15324InvestigationalORM-13070 C-11 is under investigation in clinical trial NCT00735774 (Suitability of 11C-ORM-13070 as a PET Tracer).
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. … [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction
Categories: Complement Factor D InhibitorSynonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideSpesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigationalin December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.
Melphalan
go.drugbank.com/drugs/DB01042ApprovedInvestigational[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. … Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent.
Synonyms: 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine, p-Di-(2-chloroethyl)amino-L-phenylalanineVinblastine
go.drugbank.com/drugs/DB00570ApprovedInvestigationalAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Acetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawn[L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.